Biogen FDA probe on Alzheimer's drug unlikely to have `tangible' impact, analyst says
Biogen FDA probe on Alzheimer's drug unlikely to have `tangible' impact, analyst says
SeekingAlpha
0 shares
1 views
You might like
Related news coverage
FDA Narrows Guidance On New Alzheimer's Drug Amid Criticism
Newsy
Watch VideoThe acting head of the Food and Drug Administration on Friday called for a government investigation into highly unusual..
-
FDA head calls for inquiry into Alzheimer's drug review
SeattlePI.com
-
FDA head calls for probe into Alzheimer's drug review
SeattlePI.com